RxDoctor Payments DataLook up a doctor →

David Redding, MD

Allergy & Immunology · Atlanta, GANPI 1710181391

Payments from drug & device makers

$21,993in general payments, 2019–2025

Across 870 payments — averaging $25.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Sanofi$2K
  • Regeneron Healthcare Solutions, Inc.$2K
  • CSL Behring$2K
  • GSK$2K
  • AbbVie$1K
  • plus $11K from 38 others

What the payments were for

  • Consulting fees$1501%
  • Speaking & faculty fees$2001%
  • Food & beverage$21,53298%
  • Education$1101%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,993 in reported general payments places this provider in the 75th percentile of 107 allergy & immunology providers in Georgia.

See all allergy & immunology providers in Georgia

Medicare billing

Part B allowed, 2024
$417,655
Medicare patients
93
Services billed
12,346

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TakhzyroLanadelumab-Flyo12$626,321
XolairOmalizumab34$114,916
RinvoqUpadacitinib17$104,028
Dupixent SyringeDupilumab23$82,976
OpzeluraRuxolitinib Phosphate15$30,182
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$12,583
Breo ElliptaFluticasone/Vilanterol13$9,161
SymbicortBudesonide/Formoterol Fumarate13$3,015
Ipratropium Bromide76$1,787
Azelastine Hcl64$1,246
Wixela InhubFluticasone Propion/Salmeterol17$898
Olopatadine Hcl14$602
Montelukast Sodium80$456
Albuterol Sulfate HfaAlbuterol Sulfate14$438
Fluticasone Propionate21$204

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Takhzyro$994$626,32112 claims
AbbVieRinvoq$1,258$104,02817 claims
Incyte CorporationOpzelura$525$30,18215 claims
GSKTrelegy Ellipta, Breo Ellipta$1,504$21,74333 claims
AstraZenecaSymbicort$2,505$3,01513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 107 allergy & immunology providers in Georgia.

Other allergy & immunology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →